cdk2 cyca2 (Carna Inc)
Structured Review
a " width="250" height="auto" />Cdk2 Cyca2, supplied by Carna Inc, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdk5+p25/CDK5-p25/pmc11320660-370-0-24
Average 94 stars, based on 12 article reviews
Images
1) Product Images from "A Comprehensive In Vitro Characterization of a New Class of Indole-Based Compounds Developed as Selective Haspin Inhibitors"
Article Title: A Comprehensive In Vitro Characterization of a New Class of Indole-Based Compounds Developed as Selective Haspin Inhibitors
Journal: Journal of Medicinal Chemistry
doi: 10.1021/acs.jmedchem.4c00718
a " title=" In Vitro Inhibitory Activities of Compounds against Kinase Proteinsa " property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: In Vitro Inhibitory Activities of Compounds against Kinase Proteins
Techniques Used: In Vitro
Related Articles
other:Article Title: Substituted pyrimidines as cyclin-dependent kinase inhibitors Article Snippet: CDK1/CycB, CDK5/p25 and Article Title: LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5. Article Snippet: Leucine-rich repeat kinase 2 (LRRK2) and tau have been identified as risk factors of Parkinson’s disease (PD).. As LRRK2 is a kinase and tau is hyperphosphorylated in some LRRK2 mutation carriers of PD patients, the obvious hypothesis is that tau could be a substrate of LRRK2.. Previous reports that LRRK2 phosphorylates free tau or tubulin-associated tau provide direct support for this proposition. Article Title: Substituted pyrimidines as cyclin-dependent kinase inhibitors Article Snippet: CDK1/CycB, CDK5/p25 and Article Title: Discovery and Optimization of Highly Selective Inhibitors of CDK5. Article Snippet: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent monogenic human disease, but to date, only one therapy (tolvaptan) is approved to treat kidney cysts in ADPKD patients.. Cyclin-dependent kinase 5 (CDK5), an atypical member of the cyclin-dependent kinase family, has been implicated as a target for treating ADPKD.. However, no compounds have been disclosed to date that selectively inhibit CDK5 while sparing the broader CDK family members. |
